Circulating thrombomodulin levels in familial mediterranean fever

Clinical and Experimental Rheumatology

Volumn 24, Issue 5 SUPPL. 42, 2006, Pages

  Ozbalkan, Zeynep ^a,c   Ozturk, M Akif ^b   Onat, A Mesut ^a   Ureten, Kemal ^a   Haznedaroglu, Ibrahim C ^a   Kiraz, Sedat ^a   Ertenli, A Ihsan ^a   Kirazli, Serafettin ^a   Calguneri, Meral ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Endothelial cell; Familial Mediterranean fever; Thrombomodulin

Indexed keywords

THROMBOMODULIN;

ADULT; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMAN; INFLAMMATORY CELL; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; FAMILIAL MEDITERRANEAN FEVER; FEMALE; HUMANS; MALE; THROMBOMODULIN;

EID: 33750702181     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. TUNCA M, BEN-CHETRIT E: Familial Mediterranean fever in 2003. Pathogenesis and management. Clin Exp Rheumatol 2003; 21: 49-52.
2. CENTOLA M, WOOD G, FRUTCH DM et al.: The gene for familial Mediteranean fever, MEFV, is expressed in early leukocyte development and is up-regulated in response to inflammatory mediators. Blood 2000: 95; 3223-31.
3. DIRESKENELI H, OZDOGAN H, KORKMAZ C, AKOGLU T, YAZICI H: Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever J Rheumatol 1999; 26: 1983-6.
4. AIRD WC: Endothelium as an organ. Crit Care Med 2004; 32: 271-9.
5. TAKOHASHI H, HO S, HANANO M, SEKI Y et al.: Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue type plasminogen activator. Am J Hematol 1992; 41: 32-9.
6. SHINICI O, TKADO S, MIYAKE S et al.: Plasma thrombomodulin as a marker of vascular injuries in collagen vascular disease. Am J Clin Pathol 1994; 101: 109-13.
7. TOKANO S, KIMURA S, OHDAMA S, AOKI N: Plasma thrombomodulin in health and disease. Blood 1990; 76: 2024-9.
8. ISHII H, UCHIYAMA H, KAZAMA M: Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-23.
9. CONWAY EM, NAWAKOWSKI B: Biologically active thrombomodulin is synthesized by adherent synovial fluid cells and is elevated in synovial fluid of patients with rheumatoid arthritis. Blood Feb 1993; 81: 726-33.
10. WOUVER MV, CONWAY EM: Novel functions of thrombomodulin in inflammation. Crit Care Med 2004; 32: 254-61.
11. LIVNEH A, LANGEVTIZ P, ZEMER D et al.: Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1998; 41: 1516-7.
12. MERCIE P, SEIGNEUR M, CORNI C: Plasma thrombomodulin as a marker of vascular damage in systemic sclerosis. J Rheumatol 1995; 22: 1440-1.
13. HAZNEDAROGLU IC, OZDEMIR O, OZCEBE O, DUNDAR SV, KIRAZLI S: Circulating thrombomodulin as a clue of endothelial damage in Behcet's disease. Thromb Haemost 1996; 75: 974-5.
14. KIRAZ S, ERTENLI I, BENEKLI M et al.: Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: evidence for a prothrombotic state. Lupus 1999; 8: 737-741.
15. ÇOBANKARA V, ÖZATLI D, KIRAZ S et al.: Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level. Clin Rheumatol 2004; 23: 430-4.
16. BUTANY JW, VERMA S, LEASK RL, MOHSEN B, ASA SL: Genetic abnormalities of the endothelium. Microsc Res Tech 2003; 60: 30-7.
17. BASAR O, ÖZTÜRK MA, KÖKLÜ S et al.: Serum levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in familial Mediterranean fever. Joint Bone Spine 2006 (in press).
18. ANTON PA, TARGAN SR, VIGNA SR, DURHAM M, SCHWABE AD, SHANAHAN F: Enhanced neutrophil chemiluminescence in familial Mediterranean fever. J Clin Immunol 1988; 8: 148-56.
19. KIRAZ S, ERTENLI I, ARICI M et al.: Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever. Clin Exp Rheumatol 1998; 16: 721-4.
20. VILLOUTREIX B, DAHLBACK B: Molecular model for the C-type lectin domain of human thrombomodulin. J Mol Model 1998; 4: 310-22.
21. BOFFA MC, BURKE B, HOUDENSCHILD C: Preservation of thrombomodulin antigen on vascular and extravascular surfaces. J Histochem Cytochem 1987;35:1267-76.
22. CONWAY E, NAWAKOWSKI B, STEINER-MASONYI M: Human neutrophils synthesize thrombomodulin dose not promote thrombin dependent protein C activation. Blood 1992; 80: 1254-63.
23. McCACHREN SS, DIGGS J, WEINBERG JB et al.: Thrombomodulin expression by human blood monocytes and by human synovial tissue lining macrophages. Blood 1991: 78: 3128-32.
24. SUZUKI K, NISHIOKA J, HAYASHI T et al.: Functionally active thrombomodulin is present in human platelets. J Biochem 1988; 104: 628-32.
25. MOLL S, LINDLEY C, PESCATORE S et al.: Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2004; 2: 1745-51.